Medikit (7749) Q1 2026 earnings summary

Executive summary

• Net sales for the three months ended June 30, 2025, rose 4.7% year-over-year to ¥5,890 million, while operating profit declined 5.2% to ¥1,022 million and ordinary profit decreased 3.5% to ¥1,068 million.

• Profit attributable to owners of parent fell 3.3% year-over-year to ¥392 million for the quarter.

• Comprehensive income dropped 39.6% year-over-year to ¥303 million.

Financial highlights

• Gross profit increased to ¥2,218 million from ¥2,141 million year-over-year, but selling, general and administrative expenses rose to ¥1,195 million from ¥1,062 million.

• Basic earnings per share for the quarter was ¥26.83, down from ¥27.40 in the prior year.

• Equity-to-asset ratio remained strong at 87.0% as of June 30, 2025.

• Total assets decreased to ¥51,498 million from ¥52,470 million at the end of March 2025.

• Net assets declined slightly to ¥44,801 million from ¥45,156 million at the end of March 2025.

Outlook and guidance

• Full-year net sales forecast for fiscal year ending March 31, 2026, is ¥24,000 million, up 6.4% year-over-year.

• Operating profit is projected at ¥4,500 million (up 0.3%), ordinary profit at ¥4,592 million (down 1.4%), and profit attributable to owners of parent at ¥2,924 million (down 3.0%).

• Basic earnings per share for the full year is forecast at ¥200.08.

• No revisions to previously announced earnings or dividend forecasts.